Reporting on China’s clinical research environment said government restrictions and recent patient deaths have slowed investigator-initiated trials, or IITs. The change is likely to affect the speed and cost profile that made the IIT pathway attractive for both Chinese developers and U.S. biotechs looking for faster human testing. The update frames the policy shift as a de-risking move amid scrutiny, potentially altering how sponsors structure timelines, site selection, and regulatory strategies when planning first-in-human studies. For biotech teams relying on accelerated enrollment and localized trial execution, the message is operational: China’s development pathway is tightening, with knock-on effects for global trial planning.